TRK Inhibitors: A Tumor Agnostic Targeted Therapy

For World Ovarian Cancer Day, Eirwen M. Miller, MD, discussed the current state of ovarian cancer treatment, new developments in the space, and unmet needs.

In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.

Early research suggests setanaxib combined with pembrolizumab may be a promising treatment for patients with squamous cell carcinoma of the head and neck.

In this episode of Targeted Talks, M. Michele Blackwood, MD, FACS, discusses the current landscape of breast cancer treatment and how personalized medicine with genomic testing is changing the field.

If approved, zenocutuzumab would be the first targeted therapy for neuregulin 1 fusion-positive lung and pancreatic cancers.

During a Case-Based Roundtable® event, Ulka Vaishampayan, MBBS, discussed the safety and quality-of-life data for ipilimumab plus nivolumab in patients with advanced renal cell carcinoma in the second article of a 2-part series.